Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the promising stocks to buy under $50. On January 8, Morgan Stanley analyst Maxwell Skor lowered the firm’s price target on Ultragenyx to $50 from $55 and kept an Overweight rating on the shares. The firm projects continued outperformance for US SMID-cap biotech in 2026. This bullish outlook is driven by commercial-stage companies transitioning from capital consumers to producers, combined with a looming patent cliff that threatens the revenue of large-cap biopharma.

In other news, on December 30, Ultragenyx Pharmaceutical completed its rolling BLA submission to the FDA for DTX401, which is a potential first-in-class gene therapy for Glycogen Storage Disease Type Ia/GSDIa. The application was finalized with the submission of the manufacturing/CMC module, following clinical and non-clinical data filed in August. If approved, DTX401 will address the root cause of this life-threatening metabolic disorder, which currently forces 6,000 patients worldwide to rely on rigorous, 24-hour cornstarch dosing to avoid fatal hypoglycemia.

The submission is backed by the Phase 3 GlucoGene study, which followed 52 patients for up to six years. Safety data through 96 weeks confirmed that DTX401 is well-tolerated. The therapy holds several high-priority designations, including RMAT and Fast Track, as it nears a potential commercial launch to replace the heavy dietary burden of GSDIa.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a biopharmaceutical company that identifies, acquires, develops, and commercializes novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.